SRM 003

Drug Profile

SRM 003

Alternative Names: SHP-613; SRM003; Vascugel

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Massachusetts Institute of Technology
  • Developer Shire
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral vascular disorders
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Peripheral arterial disorders; Peripheral vascular disorders

Most Recent Events

  • 17 Jul 2014 Discontinued - Phase-II for Peripheral vascular disorders in USA (Implant)
  • 23 Jul 2013 Shire restarts enrolment in two phase II trials for Peripheral vascular disorders (haemodialysis access) in USA (NCT01806545, NCT01806584)
  • 13 May 2013 Shire suspends enrolment in two phase II trials for Peripheral vascular disorders (haemodialysis access) in USA (NCT01806545, NCT01806584)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top